摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(5-chloro-2-ethylphenyl)-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide | 1553979-01-3

中文名称
——
中文别名
——
英文名称
1-(5-chloro-2-ethylphenyl)-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide
英文别名
1-(5-chloro-2-ethylphenyl)-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide
1-(5-chloro-2-ethylphenyl)-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide化学式
CAS
1553979-01-3
化学式
C19H18ClN5O
mdl
——
分子量
367.838
InChiKey
DCECDNWVAPZULO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    85.8
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS
    申请人:NERVIANO MEDICAL SCIENCES S.R.L.
    公开号:US20150166512A1
    公开(公告)日:2015-06-18
    The present invention relates to substituted pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.
    本发明涉及替代吡咯化合物,其调节蛋白激酶的活性,因此在治疗由失调的蛋白激酶活性引起的疾病中特别有用,尤其是Jak家族激酶。本发明还提供了制备这些化合物的方法,包括这些化合物的制药组合物,以及利用这些化合物或含有它们的制药组合物治疗疾病的方法。
  • Substituted pyrroles active as kinases inhibitors
    申请人:NERVIANO MEDICAL SCIENCES S.r.l.
    公开号:US10071986B2
    公开(公告)日:2018-09-11
    The present invention relates to substituted pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.
    本发明涉及取代的吡咯化合物,该化合物可调节蛋白激酶的活性,因此可用于治疗由蛋白激酶活性失调(尤其是 Jak 家族激酶)引起的疾病。本发明还提供了制备这些化合物的方法、含有这些化合物的药物组合物,以及利用这些化合物或含有这些化合物的药物组合物治疗疾病的方法。
  • US9688661B2
    申请人:——
    公开号:US9688661B2
    公开(公告)日:2017-06-27
查看更多

同类化合物

顺式-2-BOC-八氢-吡咯并[3,4-D]氮杂庚烷 羟甲磺酸二甲磺酸 环戊二烯并[4,5]氮杂卓并[2,1,7-cd]吡咯里嗪 四氢-1H-吡咯并[1,2-a]氮杂卓-3,9(2H,9aH)-二酮 吡咯并[1,2-a]氮杂-5-酮 吖庚英并[4,3-b]吲哚-1(2H)-酮,7-氟-3,4,5,6-四氢-6-甲基- 六氢-1H-吡咯并[1,2-A]氮杂卓-5(6H)-酮 N,N-二甲基-3-(3-甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)丙-1-胺 9-氟-3,4-二氢-1H-吡啶并[4,3-B]吲哚-2(5H)-羧酸叔丁酯 9-氟-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 7,8-二氢-5H-吡咯并[1,2-A]氮杂环庚烷-9(6H)-酮 6-叔-丁基3A-乙基八氢吡咯并[2,3-D]氮杂卓-3A,6(2H)-二甲酸基酯 6,7-二氢吡咯并[2,3-c]氮杂卓-4,8(1H,5H)-二酮 5H-吡咯并[1,2-a]氮杂卓-7-醇 5,9:7,11-二亚甲基-5H-吡咯并[1,2-a]吖壬英-3-羧酸,6,7,8,9,10,11-六氢-,甲基酯 4-(2-氨基-1H-咪唑-5-基)-2,3-二溴-6,7-二氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1H-咪唑-4-基)-2,3-二溴-4,5,6,7-四氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1,5-二氢-5-氧代-4H-咪唑-4-亚基)-4,5,6,7-四氢-吡咯并[2,3-c]氮杂卓-8(1H)-酮 3-苄基-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 3-(3,9-二甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)-N,N-二甲基丙烷-1-胺 2H,3H-氧杂环丁烷并[3,2-d]吡咯并[1,2-a]氮杂卓 2-碘-1,5,6,7-四氢-4H-吡咯并[3,2-C]吡啶-4-酮 2-溴-6,7-二氢-1h,5h-吡咯并[2,3-c]氮杂烷-4,8-二酮 2-溴-5,6,7,8-四氢吡咯并[3,2-C]氮杂庚烷-4(1H)-酮 2,5-已炔二醇 2,3,4,5-四氢-N,N-二甲基-2-(3,4,5-三甲氧基苯甲酰基)-氮杂卓并(3,4-b)吲哚-10(1H)-丙胺 11-氧杂-3,10-二氮杂三环[7.2.1.03,7]十二碳-1,4,6,9-四烯 1-苄基-八氢-吡咯并[3,4-b]吡啶 1,4,5,6,7,8-六氢吡咯并[3,2-b]氮杂卓 1,2,3,4,5,6-六氢氮杂环庚烷[4,3-B]吲哚盐酸盐 1,2,3,4,5,6-六氢-9-甲基氮杂卓并[4,5-b]吲哚 1,2,3,4,5,6-六氢-6-甲基氮杂革[4,5-b]吲哚盐酸盐 1,2,3,4,5,6-六氢-3-甲基氮杂卓并[4,5-b]吲哚 4-acetoxy-5,18-seco-20,21-dinor-ibogamine 3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)-1-(1-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)ethylidene)-1H-isoindole (7S,10R)-2-methyl-5-[(Z)-2-(6-methylpyridin-3-yl)vinyl]-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[b]indole 6-[(6-chloropyridin-3-yl)methyl]-9-fluoro-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole (2S,3S)-tartrate 6-[(Z)-2-(6-methylpyridin-3-yl)vinyl]-9-(trifluoromethoxy)-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole 6-[2-(6-methylpiperidin-3-yl)ethyl]-9-(trifluoromethoxy)-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole 9-methyl-6-[(Z)-2-pyridin-3-ylvinyl]-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole 8-methyl-5,15-dihydro-6H-naphtho[2',3':1,2]indolizino[8,7-b]indole-9,14-dione 4-methyl-2-(trimethylsilyl)methylsulfanyl-1-azabicyclo[5.3.0]deca-2,7,9-triene 1-(N-Methyl-2-piperidyl)cyclohexan-carbonsaeureethylester 2-methyl-1,2,3,4,5,6,7,8-octahydro-2,5-indolodiazocine 9-methyl-6-[2-(2-methylphenyl)ethyl]-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole 6-[(E)-2-pyridin-3-ylvinyl]-9-(trifluoromethoxy)-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole 6-[(Z)-2-(6-methylpyridin-3-yl)vinyl]-9-(methylsulfonyl)-3,4,5,6-tetrahydro-1H-2,5-ethanoazepino[4,3-b]indole 16α-Hydroxy-21-oxo-20ξ-dihydro-cleavamin 3-benzyl-9-methoxy-1,2,3,4,5,6-hexahydro-azepino[4,5-b]indole-8-carbaldehyde tert-butyl 3,4,5,10-tetrahydroazepino[3,4-b]indole-2(1H)-carboxylate